• Berberine Hydrochloride and the Gut–Bone Axis

  2026-08-16

  Berberine hydrochloride is moving beyond conventional metabolic and antibacterial research as a mechanistic probe of gut–bone communication. New preclinical evidence connects microbiota-derived butyrate, intestinal tuft cells, barrier repair, and osteoimmune balance, creating a disciplined framework for translational studies.

• AP20187 and Senescent CAF Assay Design

  2026-08-15

  AP20187 is a chemical inducer of dimerization that can convert static stromal models into temporally controlled assays. This article connects AP20187-driven signaling with senescent CAF biology, emphasizing causal experiment design, assay controls, and translational limitations.

• SEMA3E Drives Beige Fat Thermogenesis via β-Catenin

  2026-08-14

  The reference study identifies SEMA3E as a regulator of beige adipocyte differentiation and non-shivering thermogenesis in mice, connecting its activity to mitochondrial oxidative phosphorylation and Wnt/β-catenin signaling. Its combination of tissue-specific gene manipulation, transplantation, transcriptomics, and mitochondrial respiration assays provides a mechanistic framework for studying adipose remodeling, while leaving important questions about pathway directionality and human translation unresolved.

• Lithium, Exosomal Wnt10a, and Bone Regeneration

  2026-08-14

  The reference study identifies an exosome-centered mechanism by which lithium enhances bone mesenchymal stem cell osteogenesis: MARK2-associated Rab11a/Rab11FIP1 trafficking increases exosomal Wnt10a delivery and activates β-catenin signaling. Its comparison of lithium-conditioned exosomes with control exosomes, followed by GelMA hydrogel testing, provides a mechanistic and biomaterials framework for improving bone repair.

• Semaphorin Receptors Antagonize Wnt Signaling

  2026-08-13

  This preprint identifies Neuropilin and Plexin semaphorin receptors as previously unrecognized antagonists of Wnt signaling, acting downstream of Dishevelled to promote proteasome-dependent β-catenin destabilization. Its receptor-specific results provide a framework for separating GSK3/CK1-dependent regulation from broader pathway effects when designing Wnt-focused cell assays.

• U-73122: From PLC Signaling to Translational Insight

  2026-08-13

  U-73122 offers a practical way to interrogate phospholipase C-dependent calcium signaling, chemotaxis, inflammation, and cancer-cell invasion. This thought-leadership guide connects mechanism, assay design, evidence boundaries, and translational strategy without treating pharmacological inhibition as a substitute for pathway validation.

• IDO1 Inhibition Activates Tumor-intrinsic STAT3

  2026-08-12

  This study uses single-cell RNA sequencing to show that apo-IDO1 inhibition can activate antitumor immune cells while simultaneously inducing an IL-6–JAK2/STAT3 survival program in tumor cells. The findings provide a mechanistic rationale for combining IDO1-directed treatment with pathway-level JAK2/STAT3 inhibition, while also emphasizing the limits of translating immune activation into therapeutic benefit.

• Belinostat: Reading HDAC Response Beyond Viability

  2026-08-12

  Belinostat (PXD101) can produce both growth arrest and tumor-cell killing, making a single viability endpoint difficult to interpret. This guide presents a phenotype-centered assay framework for connecting histone deacetylase inhibition with cell-cycle, death, and translational readouts.

• SNAI1–PIK3R2/p-EphA2 Signaling in Thymic Tumors

  2026-08-11

  This 2024 study identifies SNAI1 as an oncogenic hub that links epithelial–mesenchymal transition, cancer stem cell-like traits, and macrophage remodeling in thymic epithelial tumors. Multi-omics, functional, single-cell, and biochemical analyses support a SNAI1–PIK3R2/p-EphA2–GSK3β/β-catenin signaling model and suggest that SNAI1 inhibition merits further investigation in thymic carcinoma.

• Dasatinib (BMS-354825) in Cancer Research

  2026-08-11

  Dasatinib (BMS-354825) enables pathway-focused studies of Src, Bcr-Abl, FAK, cell-cycle control, and metastatic behavior across cancer models. This practical guide connects validated product performance with assay design, the SNAI1–PIK3R2/p-EphA2 findings in thymic epithelial tumors, and troubleshooting strategies that separate target engagement from nonspecific toxicity.

• Catalpol in Alzheimer’s Disease: Mechanisms and Evidence

  2026-08-10

  The 2022 review by Chen et al. synthesizes evidence that catalpol, an iridoid glycoside from Rehmannia glutinosa, may protect against Alzheimer’s disease through antioxidant, anti-inflammatory, antiapoptotic, and broader neuroprotective actions. Its main value is mechanistic integration across interconnected pathological processes, while its translational conclusions remain limited by the heterogeneity of the underlying preclinical studies.

• MOF Nanoparticles for Non-Invasive Epilepsy Therapy

  2026-08-09

  The reference study presents ultrasound-activated piezoelectric nanoparticles built on a metal-organic framework to cross the blood–brain barrier and modulate epileptic neural activity without implanted electrodes. By combining brain-targeting ligands with platinum nanoclusters, the platform is designed to integrate neuromodulation, transport, and regulation of oxidative and inflammatory stress.

• Palonosetron Hydrochloride in 5-HT3 Assays

  2026-08-08

  Palonosetron hydrochloride combines subnanomolar 5-HT3 receptor activity with a practical route into transporter interaction studies. This workflow-focused guide covers receptor assays, OCT2/MATE1 profiling, assay controls, and troubleshooting for cancer research.

• Diuron: Mechanistic Insights and Strategic Guidance for Tran

  2026-08-07

  This article examines Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea) as a dual-use tool in plant biology and translational toxicology, integrating recent mechanistic discoveries with strategic workflow recommendations for researchers. Drawing on network toxicology, experimental validation, and APExBIO’s high-purity product, we explore the compound’s herbicidal action, nephrotoxicity, and environmental implications, offering a forward-looking perspective on risk assessment and experimental design.

• Dual-Action p38α Inhibitors Enhance Dephosphorylation Dynami

  2026-08-06

  This study uncovers a novel mechanism by which certain p38α MAP kinase inhibitors, including JNJ-3026582 (RWJ 67657), both block kinase activity and accelerate phosphatase-mediated dephosphorylation of the activation loop. These findings suggest new strategies to improve specificity and efficacy in targeting p38 MAP kinase signaling for inflammatory disease research.

16319 records 1/1088 page Next 12345 下5页 Last page